August 5, 2013 — Surgery is not always necessary for women with a type of breast tissue abnormality associated with a higher risk of cancer, according to a new study published online in the journal Radiology. Researchers said that periodic imaging and clinical exams are effective in these patients when radiology and pathology findings are benign and concordant, or in agreement.

Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) are abnormal breast lesions that occasionally appear as incidental findings in breast biopsies. Women with ALH or LCIS have a four to 10 times higher risk of developing breast cancer, according to Michael A. Cohen, M.D., FACR, professor of radiology at the Emory University School of Medicine in Atlanta. As a result, it is often recommended that ALH and LCIS diagnosed on image-guided core biopsy be removed surgically. “Because of the possibility of upgrade to cancer, the bulk of the published literature says that the prudent thing to do is excise ALH and LCIS,” Cohen said.

But new research from Cohen, Kristen Atkins, M.D., and colleagues may alter that thinking. Atkins is a pathologist and associate professor at the University of Virginia in Charlottesville. At one time, Cohen and Atkins were colleagues there and had many discussions about balancing the risk of cancer in ALH and LCIS patients with the costs and potential complications of surgery.

“From a pathology perspective, ALH and LCIS are often very tiny lesions, so we wondered why they were getting excised,” Atkins said. “These surgeries may involve general anesthesia and possible disfigurement.”

The researchers studied 10 years of pathology and radiology data to look for a correlation between the number of ALH and LCIS cases that were upgraded to cancer after surgery or follow-up and the concordance between the radiologist and pathologist. The research yielded 50 cases from 49 women aged 40 to 73 years. Radiologist and pathologist findings were concordant in 43 of the 50 cases. None of the benign concordant cases were subsequently upgraded to cancer, strongly suggesting that observation in these patients would have been a viable alternative to surgery. Of the seven discordant cases, two were upgraded to ductal carcinoma in situ (DCIS) an early-stage, noninvasive form of breast cancer.

Cohen repeated the study after moving to Emory and found the same results. “When there’s no discordance between the radiologist and pathologist after thorough radiology-pathology correlation, there’s no upgrade from ALH or LCIS to cancer in our study,” Cohen said. “These findings show that some women can avoid surgery, and that yearly mammograms along with MRI [magnetic resonance imaging] or ultrasound as second-line screening tools may suffice.”

The researchers suggested their findings will help physicians and patients make informed decisions about ALH and LCIS.

For more information: http://radiology.rsna.org


Related Content

News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
News | Breast Imaging

Dec.11, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced ...

Time December 18, 2024
arrow
News | Mammography

Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive ...

Time December 05, 2024
arrow
News | Mammography

Nov. 26, 2024 — GE HealthCare has introduced the Pristina Via* mammography system designed to enhance the screening ...

Time December 02, 2024
arrow
News | Artificial Intelligence

Dec. 2, 2024 — Lunit recently unveiled follow-up findings from the ScreenTrustCAD trial. This study, conducted at Capio ...

Time December 02, 2024
arrow
Subscribe Now